
    
      This study intends to advanced pancreatic cancer with row standard with district group random
      way is divided into two groups, a group for the gemcitabine monotherapy in the treatment
      group, another group of gemcitabine combined with low dose of decitabine treatment group. The
      overall survival, progression free survival, and disease control rate were observed in
      patients treated with combined therapy. At the same time, its safety and tolerance were
      observed. The methylation status and its influence on the immune function were also detected
      by biological test.
    
  